Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Tan

Showing results (591-600 of 640) with videos related to

Pageof 64
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneLinda T Vahdat, Brian Pruitt, Carol J Fabian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximabShirin Khambata-Ford, Christopher R Garrett, Neal J Meropol, et al.
American Journal of Hematology|May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World AnalysisMurali Janakiram, Carlyn R Tan, Hira Mian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2025
Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancerPatrick M Grierson, Crystal Wolf, Rama Suresh, et al.
JAMA Oncology|June 14, 2019
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast CancerShaveta Vinayak, Sara M Tolaney, Lee Schwartzberg, et al.
Blood Cancer Journal|May 1, 2026
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patientsRoss S Firestone, Anish K Simhal, Theresia Akhlaghi, et al.
Blood Advances|September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groupsUrvi A Shah, Erin Moshier, Andriy Derkach, et al.
Influenza and Other Respiratory Viruses|April 30, 2026
Burden of Influenza and Cost-Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in IndiaAnand Krishnan, Aslesh Ottapura Prabhakaran, Kusum Shekhawat, et al.
JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.
Diseases of the Colon and Rectum|March 6, 2023
Circumferential Resection Margin as Predictor of Nonclinical Complete Response in Nonoperative Management of Rectal CancerRe-I Chin, Joshua P Schiff, Anup S Shetty, et al.
Pageof 64

Showing results (591-600 of 640) with videos related to

Sort By:
Pageof 64
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2009
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneLinda T Vahdat, Brian Pruitt, Carol J Fabian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximabShirin Khambata-Ford, Christopher R Garrett, Neal J Meropol, et al.
American Journal of Hematology|May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World AnalysisMurali Janakiram, Carlyn R Tan, Hira Mian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2025
Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for patients with pancreatic cancerPatrick M Grierson, Crystal Wolf, Rama Suresh, et al.
JAMA Oncology|June 14, 2019
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast CancerShaveta Vinayak, Sara M Tolaney, Lee Schwartzberg, et al.
Blood Cancer Journal|May 1, 2026
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patientsRoss S Firestone, Anish K Simhal, Theresia Akhlaghi, et al.
Blood Advances|September 29, 2023
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groupsUrvi A Shah, Erin Moshier, Andriy Derkach, et al.
Influenza and Other Respiratory Viruses|April 30, 2026
Burden of Influenza and Cost-Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in IndiaAnand Krishnan, Aslesh Ottapura Prabhakaran, Kusum Shekhawat, et al.
JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.
Diseases of the Colon and Rectum|March 6, 2023
Circumferential Resection Margin as Predictor of Nonclinical Complete Response in Nonoperative Management of Rectal CancerRe-I Chin, Joshua P Schiff, Anup S Shetty, et al.
Pageof 64